Risk of developing diabetes in patients with atrial fibrillation taking non-vitamin K antagonist oral anticoagulants or warfarin: A nationwide cohort study.
Liu, Peter Pin-Sung
Peng, Carol Chiung-Hui
Munir, Kashif M
JournalDiabetes, Obesity & Metabolism
MetadataShow full item record
AbstractAim: To compare the risk of diabetes development in patients with atrial fibrillation (AF) treated with non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin. Materials and Methods: We conducted a nationwide retrospective cohort study using Taiwan's National Health Insurance Research Database. Adult patients with new onset of AF, treated with NOACs or warfarin between 2012 and 2016, were included. The NOAC cohort was further divided into dabigatran, rivaroxaban and apixaban groups. The primary outcome was incident diabetes requiring treatment with antidiabetic drugs. Fine and Gray subdistribution hazards models were used to estimate the adjusted hazard ratio (aHR). Propensity score matching was performed for each head-to-head comparison. Results: A total of 10 746 new-onset AF patients were included in our study. During the mean 2.4-year follow-up, NOACs were associated with a lower risk of developing diabetes than warfarin (aHR = 0.80, 95% confidence interval [CI]: 0.68-0.94, P =.007). Subgroup analyses confirmed that dabigatran, rivaroxaban and apixaban each had a reduced diabetes risk. Stratified analyses showed that the lower risk of diabetes associated with NOAC treatment was specific to patients aged 65 years or older (aHR = 0.74, 95% CI: 0.62-0.89, P =.002) and those with good medication adherence (aHR = 0.70, 95% CI: 0.58-0.84, P <.001). Conclusions: Taking an NOAC was associated with a lower risk of developing diabetes than taking warfarin in patients with AF.
Rights/Terms© 2020 John Wiley & Sons Ltd.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/14189
- Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non-Vitamin K Antagonist Oral Anticoagulants or Warfarin.
- Authors: Huang HK, Liu PP, Hsu JY, Lin SM, Peng CC, Wang JH, Yeh JI, Loh CH
- Issue date: 2020 Jan 21
- Fracture risks among patients with atrial fibrillation receiving different oral anticoagulants: a real-world nationwide cohort study.
- Authors: Huang HK, Liu PP, Hsu JY, Lin SM, Peng CC, Wang JH, Loh CH
- Issue date: 2020 Mar 7
- Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
- Authors: Nielsen PB, Skjøth F, Søgaard M, Kjældgaard JN, Lip GY, Larsen TB
- Issue date: 2017 Feb 10
- Association of Ischemic Stroke, Major Bleeding, and Other Adverse Events With Warfarin Use vs Non-vitamin K Antagonist Oral Anticoagulant Use in Patients With Atrial Fibrillation With a History of Intracranial Hemorrhage.
- Authors: Tsai CT, Liao JN, Chiang CE, Lin YJ, Chang SL, Lo LW, Hu YF, Tuan TC, Chung FP, Chao TF, Lip GYH, Chen SA
- Issue date: 2020 Jun 1
- Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
- Authors: Graham DJ, Baro E, Zhang R, Liao J, Wernecke M, Reichman ME, Hu M, Illoh O, Wei Y, Goulding MR, Chillarige Y, Southworth MR, MaCurdy TE, Kelman JA
- Issue date: 2019 May